List view / Grid view
15 December 2011 | By GlaxoSmithKline
Study to enrol over 800 adult patients with systemic lupus erythematosus...
15 December 2011 | By AstraZeneca
AstraZeneca announced that the German assessment body, the Federal Joint Committee (G-BA), has issued its final decision regarding the medical benefit of BRILIQUE (ticagrelor)...
14 December 2011 | By kdm communications limited
Syrris, offers a range of reactors designed specifically for applications requiring elevated pressures...
14 December 2011 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the company intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai...
13 December 2011 | By Novartis
Results from two pivotal Phase III trials...
12 December 2011 | By Pfizer
Pfizer Inc. has announced that its Board of Directors has elected Ian Read, as Chairman of the Board and CEO, effective immediately...
12 December 2011 | By Abbott
Agreement calls for 50/50 global profit share for multiple new molecules...
12 December 2011 | By Eli Lilly and Company
Board of Directors of Eli Lilly and Company has elected Katherine Baicker, Ph.D. as a new member, effective December 12, 2011...
12 December 2011 | By ICON plc
ICON plc, has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting Ltd., a leading CRO in China...
12 December 2011 | By Elan Corporation, plc
€3m grant to combine business & science disciplines at University College Dublin...
12 December 2011 | By B&W Tek, Inc.
B&W Tek, Inc., announced its newest strategic partnership with Gnosys Global, Ltd...
12 December 2011 | By Merck
ZOLINZA in combination with Bortezomib achieved primary endpoint of improved progression-free survival in patients with relapsed and/or refractory multiple myeloma in Phase III trial...
12 December 2011 | By Novartis
Phase III clinical trial data presented...
12 December 2011 | By Eli Lilly and Company
Data from an oncology pipeline molecule announced at the ASH meeting...
9 December 2011 | By Boehringer Ingelheim
The final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335...
